Literature DB >> 10678839

Treating young patients with breast cancer. The evidence suggests that all should be treated with adjuvant therapy.

J M Dixon, G Hortobagyi.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10678839      PMCID： PMC1127512          DOI： 10.1136/bmj.320.7233.457

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

Review 1.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

Authors:  A Goldhirsch; J H Glick; R D Gelber; H J Senn
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

2.  Radiotherapy and chemotherapy in high-risk breast cancer.

Authors:  A Goldhirsch; A S Coates; M Colleoni; R D Gelber
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

4.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  R Day; P A Ganz; J P Costantino; W M Cronin; D L Wickerham; B Fisher
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Factors influencing the effect of age on prognosis in breast cancer: population based study.

Authors:  N Kroman; M B Jensen; J Wohlfahrt; H T Mouridsen; P K Andersen; M Melbye
Journal:  BMJ       Date:  2000-02-19

6.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

7.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer.

Authors:  A J Nixon; D Neuberg; D F Hayes; R Gelman; J L Connolly; S Schnitt; A Abner; A Recht; F Vicini; J R Harris
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

8.  The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.

Authors:  T J Smith; B E Hillner
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

9.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

Authors:  G Bonadonna; M Zambetti; P Valagussa
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

10.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321
  10 in total
  1 in total

1.  A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.

Authors:  Silvia Dellapasqua; Vincenzo Bagnardi; Meredith M Regan; Nicole Rotmensz; Mauro G Mastropasqua; Giuseppe Viale; Eugenio Maiorano; Karen N Price; Richard D Gelber; Monica Castiglione-Gertsch; Aron Goldhirsch; Marco Colleoni
Journal:  Breast       Date:  2012-06-29       Impact factor: 4.380
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.